AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER).
Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.
| Metabolism | Amino acids are metabolized via transamination, deamination, and Krebs cycle; dextrose is metabolized via glycolysis, pyruvate oxidation, and the citric acid cycle. |
| Excretion | Renal: >90% as amino acids and metabolites; biliary/fecal: minimal (<2%) |
| Half-life | Amino acids: 0.5-2 hours; dextrose: 1-4 hours in non-diabetic patients; context: reflects rapid uptake and metabolism |
| Protein binding | Amino acids: minimal (<10%; primarily albumin); dextrose: negligible |
| Volume of Distribution | 0.2-0.5 L/kg; reflects distribution into extracellular fluid and lean body mass |
| Bioavailability | Intravenous: 100% |
| Onset of Action | Intravenous: within 30 minutes (nitrogen balance improvement, blood glucose elevation) |
| Duration of Action | Amino acids: 4-6 hours (protein synthesis stimulation); dextrose: 2-4 hours (hyperglycemia risk persists with continuous infusion) |
Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 50 mL/min: reduce dose to 0.5-0.8 g amino acids/kg/day. For GFR < 15 mL/min or dialysis: consider essential amino acid formulations; avoid in severe renal failure unless specifically indicated. |
| Liver impairment | Child-Pugh A: no adjustment required. Child-Pugh B: reduce to 0.8-1.0 g amino acids/kg/day. Child-Pugh C: restrict to 0.5-0.8 g amino acids/kg/day. Caution in encephalopathy; use branched-chain amino acid enriched solutions if indicated. |
| Pediatric use | Infants and children: 2-3 g amino acids/kg/day via central vein. Monitor electrolytes and growth parameters. Adjust based on age, weight, and clinical condition. |
| Geriatric use | Elderly: initiate at lower end of adult range (1.0 g amino acids/kg/day) and titrate gradually. Monitor renal function and fluid status closely due to reduced physiological reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER).
| Breastfeeding | No data on excretion in breast milk. Dextrose and amino acids are normal milk components. Caution with high dextrose load due to potential infant hyperglycemia. M/P ratio unknown. |
| Teratogenic Risk | Insufficient human data; animal studies not conducted. Dextrose 25% may cause maternal hyperglycemia, fetal hyperinsulinism, and neonatal hypoglycemia if administered near term. Use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None. However, parenteral nutrition products may be associated with serious complications including infection, metabolic alterations, and catheter-related complications.
| Serious Effects |
["Hypersensitivity to any component","Inborn errors of amino acid metabolism","Severe hyperglycemia or uncontrolled diabetes","Severe electrolyte disturbances","Acute myocardial infarction or pulmonary edema (due to dextrose load)"]
| Precautions | ["Monitor for signs of infection at the infusion site or systemically","Assess fluid and electrolyte balance regularly","Evaluate renal and hepatic function","Monitor blood glucose levels to avoid hyperglycemia or hypoglycemia","Use with caution in patients with severe renal impairment, hepatic failure, or metabolic disorders"] |
| Food/Dietary | No oral food interactions as this is parenteral nutrition. However, if transitioning to oral diet, monitor for refeeding syndrome and adjust accordingly. |
Loading safety data…
| Monitor maternal blood glucose, electrolytes, fluid balance. Fetal monitoring for signs of distress or hyperinsulinism. Assess for neonatal hypoglycemia post-delivery. |
| Fertility Effects | No known direct effect on fertility. Underlying nutritional status may influence reproductive function. |
| Clinical Pearls | Monitor serum electrolytes, glucose, and renal function daily. Use central line administration only due to high osmolarity (approx. 2100 mOsm/L). Taper rate gradually to avoid rebound hypoglycemia in prolonged use. Contraindicated in patients with severe electrolyte imbalances, hepatic coma, or known allergy to amino acids. |
| Patient Advice | This solution provides complete nutrition through a vein; you will be monitored frequently for blood sugar and electrolyte levels. · Report any signs of infection at the catheter site, shortness of breath, or swelling in your legs. · Do not stop the infusion suddenly; the rate will be gradually reduced to prevent low blood sugar. |